US court rules abortion pill restrictions 'unlawful'
medicalxpress - A federal court in Virginia has ruled that restrictions imposed by the U.S. drug regulator on the abortion pill mifepristone are "unlawful" and ordered the Trump administration to reconsider them.
AI Summary: A U.S. court ruled recent restrictions on the abortion pill unlawful, reaffirming FDA regulatory standards and restoring broader access. Industry groups filed briefs backing FDA oversight, warning that legal uncertainty would harm patients and research. The ruling calms access for now while legal and policy debates continue.
DHS finalizes 4-year visa limit for international physician training
Paige Twenter / beckershospitalreview - On July 17, the Department of Homeland Security finalized a rule capping U.S. stays for international students and exchange visitors at four years, ending the open-ended “duration of status” framework for medical trainees. Here are six things to know: 1. …
AI Summary: The Department of Homeland Security finalized new visa policies that alter the duration and structure of certain training‑related visas for international physicians, decoupling program length from visa terms. The changes aim to tighten immigration controls while raising concerns about workforce planning and the pipeline of internationally trained clinicians in U.S. health systems.
AHRQ terminates dozens of patient care research grants: Report
Elizabeth Gregerson / beckershospitalreview - HHS’ Agency for Healthcare Research and Quality has begun to terminate funding for research related to strengthening patient safety, care delivery, clinical practice and policy, and workforce training, according to a July 16 report from AcademyHealth. Aca…
AI Summary: The Agency for Healthcare Research and Quality has discontinued dozens of active research awards focused on patient care, citing programmatic changes and funding shifts. The abrupt terminations leave investigators scrambling and could slow progress on projects aimed at improving clinical practice and outcomes—proof that research pipelines are only as sturdy as their funding lines.
Molina Healthcare plans more marketplace exits as ACA segment falters
fiercehealthcare - Molina Healthcare is planning further reductions in its marketplace business as high costs continue to pressure that segment, the company's top brass told investors on Thursday morning.
AI Summary: Molina Healthcare announced plans to withdraw from additional Affordable Care Act marketplaces, citing financial challenges and market pressures. The move signals growing instability for some insurers in the ACA exchange space and could limit options for consumers in affected regions, while reigniting debates about market design and access.
- Hospitals and employers feel squeeze as uninsured rates climb (4)
- Insurers retreat from ACA exchanges, sparking debate over causes (4)
Hospitals and employers feel squeeze as uninsured rates climb
Insurers retreat from ACA exchanges, sparking debate over causes
US actions harm global efforts to prevent and treat HIV in dozens of countries, new report says
medicalxpress - The Trump administration's disruptions to a global AIDS relief program have forced organizations to close clinics, lay off staff and cut services, seriously impeding efforts to prevent and treat the disease in dozens of countries, a new report released Tu…
AI Summary: A new analysis concludes recent U.S. policy shifts have weakened international HIV prevention and treatment initiatives, disrupting funding flows and partnership stability. Public health experts caution the changes could reverse progress in vulnerable regions, urging policymakers to recalibrate support to sustain global gains against HIV/AIDS.
Children's cereals promise breakfast fun and nutrition, but are still high in sugar
medicalxpress - Many of us have grown up hearing the mantra that breakfast is the most important meal of the day, yet children's cereals fall short of that standard. That is the takeaway of new research analyzing child-targeted cereals in Canada.
AI Summary: Two investigative reports show major children's breakfast cereals remain high in added sugars despite branding that implies nutrition and fun. Public health advocates warn the products contribute to unhealthy diets in kids and call for clearer labeling and stricter marketing standards to parents and regulators.
D.C. appeals court sides with HHS in 340B drug discount program rebate challenge
fiercehealthcare - The ruling upheld a previous decision that pharma companies cannot impose rebates without HHS Secretary approval.
AI Summary: The D.C. appeals court sided with HHS in a legal challenge over 340B drug discount rebates, affirming federal authority over the program’s rebate models. The ruling preserves HHS policy changes that influence pricing and hospital participation, potentially reshaping pharmacy discounts and provider finances nationwide.
- Appeals court and federal rulings cement HHS 340B authority (3)
- CMS reimbursement shakeup: winners, losers and litigation fallout (3)
- HRSA’s revised 340B rebate pilot and oversight push (3)
Appeals court and federal rulings cement HHS 340B authority
CMS reimbursement shakeup: winners, losers and litigation fallout
HRSA’s revised 340B rebate pilot and oversight push
Key Republican Senator Says He Will Support Erica Schwartz for C.D.C. Director
Sheryl Gay Stolberg / nytimes - Senator Bill Cassidy, who is believed to hold the deciding vote in the Senate health committee for Dr. Erica Schwartz’s confirmation, had declined for days to say whether he would back her.
AI Summary: A leading Republican senator announced support for Dr. Erica Schwartz’s nomination to lead the CDC, bolstering bipartisan momentum amid a contentious confirmation process. The endorsement could smooth Senate consideration by narrowing opposition and signaling pragmatic cooperation on public health leadership.
6-year-old in China dies after experimental treatment, investigation finds, raising questions about the country's gene therapy regulations
livescience - A young girl in China died after being given an experimental gene therapy intended to treat a neurodevelopmental syndrome, an investigation by Science and Retraction Watch revealed.
AI Summary: An investigation found a six‑year‑old patient died following an experimental gene‑editing treatment in China, and that the fatality was not promptly disclosed. The case has reignited scrutiny of the country’s gene therapy oversight and raised urgent questions about trial transparency, consent and regulatory enforcement.